Physician profile
Stan Mays
NPI 1851360622
$15,147.71
in general payments reported to CMS, 2019-2025
37 companies · $2,416 in 2025
The $2,416 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,332 · 2020: $1,901 · 2021: $2,080 · 2022: $2,251 · 2023: $2,300 · 2024: $1,868 · 2025: $2,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,999 · Education: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,999.24 |
| Education | $584.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,110.43 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,510.72 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,341.61 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,127.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,075.72 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,057.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $973.74 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Novartis Pharmaceuticals Corporation | $841.89 | 2019-2025 | |
| Lilly USA, LLC | $837.11 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $609.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $519.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $499.96 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $443.85 | 2023-2025 | Gemtesa |
| Pfizer INC. | $293.83 | 2020-2024 | |
| Hikma Pharmaceuticals USA | $243.40 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $236.00 | 2019-2022 | |
| Abbvie INC. | $205.10 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $172.84 | 2023-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $151.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $146.24 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $100.53 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $98.63 | 2022 | |
| Abbott Laboratories | $88.87 | 2021-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $80.20 | 2022 | |
| Ardelyx, INC. | $64.79 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $46.62 | 2019 | |
| Insulet Corporation | $44.65 | 2025 | Omnipod |
| Mannkind Corporation | $42.50 | 2025 | |
| Idorsia Pharmaceuticals US INC | $35.31 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $28.04 | 2019 | |
| Renalytix Ai, INC. | $23.49 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Avanir Pharmaceuticals, INC. | $21.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.02 | 2023 | Nuedexta |
| Global Blood Therapeutics, INC. | $14.99 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.05 | 2020 | |
| Athena Bioscience, LLC | $12.33 | 2023 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stan Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.